Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record.

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

Open access
Jabbari, Ali, Dai, Zhenpeng, Xing, Luzhou, Cerise, Jane E., Ramot, Yuval, Berkun, Yackov, Sanchez, Gina A. Montealegre, Goldbach-Mansky, Raphaela, Christiano, Angela M., Clynes, Raphael, Zlotogorski, Abraham·2015·EBioMedicine

Abstract

BACKGROUND: Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules. METHODS: A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. In vivo, preclinical studies were conducted using the C3H/HeJ AA mouse model to assess the mechanism of clinical improvement by baricitinib. FINDINGS: The patient exhibited a striking improvement of his AA on baricitinib over several months. In vivo studies using the C3H/HeJ mouse model demonstrated a strong correlation between resolution of the interferon signature and clinical improvement during baricitinib treatment. INTERPRETATION: Baricitinib may be an effective treatment for AA and warrants further investigation in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2015.02.015

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 233

Metadata

Authors
Jabbari, A., Dai, Z., Xing, L., Cerise, J. E., Ramot, Y., Berkun, Y., Sanchez, G. A. M., Goldbach-Mansky, R., Christiano, A. M., Clynes, R., & Zlotogorski, A.
Venue
EBioMedicine
Publisher
Elsevier BV
Published
2015-04
Volume
2
Issue
4
Pages
351-355
ISSN
2352-3964 (ISSN-L)
OpenAlex
W2105110037
Cited by
233
References
0
FWCI
36.92
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. https://app.cochat.ai/papers/10.1016/j.ebiom.2015.02.015
The paper
Jabbari, A., Dai, Z., Xing, L., Cerise, J. E., Ramot, Y., Berkun, Y., Sanchez, G. A. M., Goldbach-Mansky, R., Christiano, A. M., Clynes, R., & Zlotogorski, A. (2015). Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. https://doi.org/10.1016/j.ebiom.2015.02.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.